The Life Sciences team advised SciNeuro Pharmaceuticals on entering into a worldwide licensing and collaboration agreement with Novartis Pharma AG, to advance SciNeuro’s novel amyloid beta targeted antibody program for the treatment of Alzheimer’s Disease. The program has identified de novo antibody candidates that incorporate SciNeuro’s proprietary blood brain barrier shuttle technology and offer potential differentiation from existing amyloid beta targeted agents.
Under the terms of the agreement, SciNeuro will receive an upfront payment of $165 million. In addition, SciNeuro is eligible to receive research funding, and potentially up to $1.5 billion in development, regulatory, and commercial milestones, as well as tiered royalties.
SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration – neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatment options for Alzheimer’s disease, Parkinson’s disease, and other devastating CNS diseases.
The Goodwin deal team was led by Wenseng 'Wendy' Pan and consisted of Christopher Zhong and Kevin Guan (Life Sciences); Justin Pierce, Gozde Guckaya and Nick Ognibene (Global Trade) and Paul Jin, Ortal Ben Aharon and Arom Yun (Antitrust).
For more information on the deal, please read the press release.